Sheheryar Kabraji
Hematology & Oncology · Buffalo, NYNPI 1326369562
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,930 of the $3,955 with a category attached, or 99.4%. 3 manufacturers reported payments, led by AstraZeneca at 56.6% of the total.
Across 4 payments — averaging $988.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Daiichi Sankyo Inc.$960
- Gilead$755
Across 1 payment — averaging $245,391 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$245K
What the payments were for
- Consulting fees$3,93099%
- Food & beverage$251%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $2,240 |
| Daiichi Sankyo Inc. | 1 | $960 |
| Gilead | 2 | $755 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,955 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 15 | $241,104 |
| IbrancePalbociclib | 11 | $171,546 |
| Letrozole | 53 | $1,457 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Buffalo
- Eunice WangBuffalo$295K
- Grace DyBuffalo$135K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.